DOSISPHERE-01 Trial Data
The DOSISPHERE-01 trial showed how personalized TheraSphere dosimetry improved tumor response and survival in advanced HCC patients. The results showed personalized dosimetry improved the Objective Response Rate to 71.4% versus 35.7% with standard dosimetry. It also improved median Overall Survival by 16 months versus standard dosimetry. Personalized dosimetry downstaged more unresectable patients to surgery and showed better results in patients with Portal Vein Thrombosis (PVT).